-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
RenovoRx (NASDAQ:RNXT) Stock Price Down 7.6%
RenovoRx (NASDAQ:RNXT) Stock Price Down 7.6%
RenovoRx, Inc. (NASDAQ:RNXT – Get Rating)'s stock price traded down 7.6% during trading on Wednesday . The stock traded as low as $3.54 and last traded at $3.65. 354,715 shares traded hands during trading, an increase of 346% from the average session volume of 79,574 shares. The stock had previously closed at $3.95.
RenovoRx Stock Performance
The company has a market cap of $33.11 million, a price-to-earnings ratio of -3.72 and a beta of 0.25. The stock's fifty day moving average is $2.23 and its two-hundred day moving average is $2.13.
Get RenovoRx alerts:RenovoRx (NASDAQ:RNXT – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. On average, equities research analysts expect that RenovoRx, Inc. will post -1.11 EPS for the current year.
Hedge Funds Weigh In On RenovoRx
Large investors have recently bought and sold shares of the stock. Colony Group LLC purchased a new stake in shares of RenovoRx in the third quarter valued at about $32,000. Vanguard Group Inc. bought a new position in shares of RenovoRx during the 1st quarter worth approximately $32,000. Bank of America Corp DE bought a new position in shares of RenovoRx in the first quarter valued at approximately $44,000. Cohen Lawrence B increased its position in shares of RenovoRx by 79.5% during the second quarter. Cohen Lawrence B now owns 97,165 shares of the company's stock valued at $192,000 after acquiring an additional 43,044 shares during the last quarter. Finally, Bank of The West bought a new stake in RenovoRx during the second quarter worth $1,931,000. 13.56% of the stock is currently owned by institutional investors.RenovoRx Company Profile
(Get Rating)
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
Featured Stories
- Get a free copy of the StockNews.com research report on RenovoRx (RNXT)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
RenovoRx, Inc. (NASDAQ:RNXT – Get Rating)'s stock price traded down 7.6% during trading on Wednesday . The stock traded as low as $3.54 and last traded at $3.65. 354,715 shares traded hands during trading, an increase of 346% from the average session volume of 79,574 shares. The stock had previously closed at $3.95.
RenovorX, Inc.（纳斯达克股票代码：RNXT — 获取评级）的股价在周三的交易中下跌了7.6％。该股的交易价格低至3.54美元，最后一次交易价格为3.65美元。交易期间有354,715股股票交易，较79,574股的平均交易量增长了346％。该股此前收于3.95美元。
RenovoRx Stock Performance
RenovorX 股票表现
The company has a market cap of $33.11 million, a price-to-earnings ratio of -3.72 and a beta of 0.25. The stock's fifty day moving average is $2.23 and its two-hundred day moving average is $2.13.
该公司的市值为3311万美元，市盈率为-3.72，beta值为0.25。该股的五十天移动平均线为2.23美元，其两百天移动平均线为2.13美元。
RenovoRx (NASDAQ:RNXT – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. On average, equities research analysts expect that RenovoRx, Inc. will post -1.11 EPS for the current year.
RenovorX（纳斯达克股票代码：RNXT — Get Rating）上次发布季度收益数据是在11月14日星期一。该公司公布了本季度每股收益（0.24美元），比市场普遍预期的（0.27美元）高出0.03美元。股票研究分析师平均预计，RenovorX, Inc.今年每股收益将为-1.11美元。
Hedge Funds Weigh In On RenovoRx
对冲基金对 RenovorX 进行了权衡
RenovoRx Company Profile
RenovorX 公司简介
(Get Rating)
（获取评分）
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
RenovorX, Inc是一家临床阶段的生物制药公司，专注于开发治疗实体瘤的疗法。其主要候选产品是RenovoGem，这是一种由动脉内吉西他滨和RenovoCath组成的药物和器械组合，目前正在进行局部晚期胰腺癌的III期临床试验。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on RenovoRx (RNXT)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- 免费获取 StockNews.com 关于 RenovorX (RNXT) 的研究报告的副本
- 宝洁公司收益：一场值得一试的赌博
- 股市下滑，经济报告描绘了经济的阴暗前景
- Nu Holdings 的股票与沃伦·巴菲特有什么关系？
- J.B. Hunt 持平，物流公司成为人们关注的焦点
- 英特尔股票即将爆发吗？
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 RenovorX 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收RenovorX及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧